Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct 31:8:490.
doi: 10.3389/fonc.2018.00490. eCollection 2018.

GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Pathogenic Variant Carriers

Fabienne Lesueur  1 , Noura Mebirouk  1 , Yue Jiao  2 , Laure Barjhoux  3 , Muriel Belotti  2 , Maïté Laurent  2 , Mélanie Léone  4 , Claude Houdayer  2 , Brigitte Bressac-de Paillerets  5 , Dominique Vaur  6 , Hagay Sobol  7 , Catherine Noguès  7 , Michel Longy  8 , Isabelle Mortemousque  9 , Sandra Fert-Ferrer  10 , Emmanuelle Mouret-Fourme  2 , Pascal Pujol  11 , Laurence Venat-Bouvet  12 , Yves-Jean Bignon  13 , Dominique Leroux  14 , Isabelle Coupier  11 , Pascaline Berthet  6 , Véronique Mari  15 , Capucine Delnatte  16 , Paul Gesta  17 , Marie-Agnès Collonge-Rame  18 , Sophie Giraud  4 , Valérie Bonadona  19   20 , Amandine Baurand  21 , Laurence Faivre  21 , Bruno Buecher  2 , Christine Lasset  19   20 , Marion Gauthier-Villars  2 , Francesca Damiola  3 , Sylvie Mazoyer  22 , Sandrine M Caputo  2 , Nadine Andrieu  1 , Dominique Stoppa-Lyonnet  2   23 ; GEMO Study Collaborators
Affiliations

GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Pathogenic Variant Carriers

Fabienne Lesueur et al. Front Oncol. .
No abstract available

Keywords: BRCA1/2 mutation carriers; DNA banking; breast cancer; genetic epidemiology; pathogenic variant (PV).

PubMed Disclaimer

Figures

Figure 1
Figure 1
Distribution and occurrence of pathogenic variants along BRCA1 (A) and BRCA2 (B) in probands in the GEMO study. BRCA1 domains are: RING domain, Coiled Coil domains, BRCT (BRCA1 C-terminal) domains (14, 27). BRCA2 domains are: BRC repeats, helical domain (HD), OB fold binding domains, tower alpha (14, 28). Breast cancer risk regions: LR1, lower risk region in BRCA1, LR2 lower risk region in BRCA2, HR2, higher risk region in BRCA2 (29); BCCR, breast cancer cluster region (14); Ovarian cancer risk regions: OCCR, ovarian cancer cluster region (14).
See this image and copyright information in PMC

References

    1. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. . Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Breast Cancer Linkage Consort Am J Hum Genet. (1998) 62:676–89. 10.1086/301749 - DOI - PMC - PubMed
    1. Hopper JL, Southey MC, Dite GS, Jolley DJ, Giles GG, Mccredie MR, et al. . Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Aust Breast Cancer Family Study Cancer Epidemiol Biomarkers Prev. (1999) 8:741–7. - PubMed
    1. Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA, et al. . The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer (2008a) 98:1457–66. 10.1038/sj.bjc.6604305 - DOI - PMC - PubMed
    1. Brohet RM, Velthuizen ME, Hogervorst FB, Meijers-Heijboer HE, Seynaeve C, Collee MJ, et al. . Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations. J Med Genet. (2014) 51:98–107. 10.1136/jmedgenet-2013-101974 - DOI - PubMed
    1. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. . Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA (2017) 317:2402–16. 10.1001/jama.2017.7112 - DOI - PubMed